J2329 — Injection, ublituximab-xiiy, 1mg
J2329 is a HCPCS Level II code for injection, ublituximab-xiiy, 1mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusE
Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
The CMS record for J2329
- Long descriptor
- Injection, ublituximab-xiiy, 1mg
- Short descriptor
- Inj ublituximab-xiiy, 1 mg
- Added
- July 1, 2023
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J2329
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J2329 is not quite right, the correct code is very often within a few positions of it.
- J2312Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315Injection, naltrexone, depot form, 1 mg
- J2320Injection, nandrolone decanoate, up to 50 mg
- J2323Injection, natalizumab, 1 mg
- J2325Injection, nesiritide, 0.1 mg
- J2326Injection, nusinersen, 0.1 mg
- J2327Injection, risankizumab-rzaa, intravenous, 1 mg
- J2350Injection, ocrelizumab, 1 mg
- J2351Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
- J2353Injection, octreotide, depot form for intramuscular injection, 1 mg
- J2354Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
- J2355Injection, oprelvekin, 5 mg
- J2356Injection, tezepelumab-ekko, 1 mg
- J2357Injection, omalizumab, 5 mg
- J2358Injection, olanzapine, long-acting, 1 mg
Questions about J2329
What is HCPCS code J2329?
J2329 is a HCPCS Level II code for injection, ublituximab-xiiy, 1mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J2329?
The CMS HCPCS file marks J2329 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
How is J2329 paid under the physician fee schedule?
J2329 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).